Zofin (Organicell Flow) for Patients With COVID-19
A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Moderate to SARS Related to COVID-19 Infection vs Placebo
Sponsor: ZEO ScientifiX, Inc.
Listed as NCT04384445, this PHASE1/PHASE2 trial focuses on Acute Respiratory Distress Syndrome and COVID-19 and remains completed. Sponsored by ZEO ScientifiX, Inc., it has been updated 11 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2023 — May 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 6 earlier versions
-
Mar 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jun 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ZEO ScientifiX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .